Pinaverium is a spasmolytic agent used for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function.
- Mechanism
- Curator reviewed · 4 references
Pinaverium interacts with the 1,4-dihydropyridine binding sites on voltage dependent L-type calcium channels located on GI smooth muscle cells in a competitve manner. The binding site is located in the alpha 1S subunit and pinaverium most likely antagonizes the action of calcium ions by stabilizing a non-conducting channel state. Pinaverium inhibits smooth muscle contractions of the GI tract by inhibiting inward calcium current and calcium influx. It is suggested that pinaverium may be able to bind to both closed or inactivates states of the calcium channel with similar affinity.
- Primary indication
- Pinaverium is indicated for the symptomatic treatment of irritable bowel syndrome (IBS) and functional disorders of the biliary tract.Curator reviewed · 5 structured indications
- Formula / weight
- C26H41BrNO4 · 511.52 g/mol (avg)
- First approval
- Canada, 2015
- Brand names
Resolves to
DDHUTBKXLWCZCO-UHFFFAOYSA-NSMILESCOC1=C(OC)C=C(C[N+]2(CCOCCC3CCC4CC3C4(C)C)CCOCC2)C(Br)=C1What you can answer from here — as of August 30, 2026
Which drugs share a target with Pinaverium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account